PMID- 38292895
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240201
IS  - 1662-4548 (Print)
IS  - 1662-453X (Electronic)
IS  - 1662-453X (Linking)
VI  - 17
DP  - 2023
TI  - Efficacy and safety of zuranolone in the treatment of major depressive disorder: 
      a meta-analysis.
PG  - 1332329
LID - 10.3389/fnins.2023.1332329 [doi]
LID - 1332329
AB  - OBJECTIVE: This study aimed to systematically review zuranolone's efficacy and 
      safety in treating major depressive disorder (MDD). METHODS: We conducted 
      electronic searches in databases like PubMed, Embase, Cochrane, and Web of 
      Science to identify randomized controlled trials using zuranolone for severe 
      depression from study inception to September 15, 2023. Two independent reviewers 
      screened studies, extracted data, and assessed study quality. Our meta-analysis 
      included four studies with 1,454 patients. The findings showed significant 
      improvements with zuranolone across various measures: Hamilton Depression Rating 
      Scale (HAM-D) scores indicated notable alleviation in depressive symptoms (WMD: 
      -2.03; 95% CI: -2.42 to -1.65); the treatment group's HAM-D score response rate 
      was significantly higher than the control group's at day 15 (OR: 1.46, 95% CI: 
      1.11 to 1.92, P = 0.01). The meta-analysis also revealed higher remission rates 
      for the treatment group compared to the control group at day 15 (OR: 1.68, 95% 
      CI: 1.18 to 2.39, P = 0.03). Additionally, HAM-A scores on day 15 and MADRS 
      scores on day 15 showed improvement, and HAM-D scores for 30 mg zuranolone on 
      different treatment days exhibited improvement (WMD, -2.55; 95% CI, -3.24 to 
      -1.58; P = 0.05). However, analyzing HAM-D scores on day 15 for various 
      zuranolone doses revealed no significant differences. Importantly, zuranolone use 
      was associated with an increased incidence of adverse reactions. RESULTS: Our 
      meta-analysis included four studies with 1454 patients, showing significant 
      improvements with zuranolone across various measures, including HAM-D scores, 
      HAM-A scores, MADRS scores, and specific HAM-D scores for 30 mg zuranolone on 
      different treatment days. However, no significant differences were found in HAM-D 
      scores on day 15 for various doses of zuranolone. CONCLUSIONS: Our findings 
      suggest that zuranolone is a promising, simple, and convenient treatment for 
      patients with major depressive disorder, offering potential guidance for clinical 
      practice.
CI  - Copyright (c) 2024 Wang, Zhang, Liu, Zhang, Wang and Li.
FAU - Wang, Shuyu
AU  - Wang S
AD  - School of Basic Medical Science, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Zhang, Wenxing
AU  - Zhang W
AD  - School of Basic Medical Science, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Liu, Zhang
AU  - Liu Z
AD  - School of Basic Medical Science, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Zhang, Tian
AU  - Zhang T
AD  - School of Basic Medical Science, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Wang, Yi
AU  - Wang Y
AD  - School of Basic Medical Science, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Li, Weihong
AU  - Li W
AD  - School of Basic Medical Science, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
LA  - eng
PT  - Systematic Review
DEP - 20240116
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC10824890
OTO - NOTNLM
OT  - MDD
OT  - SAGE-217
OT  - depression
OT  - major depressive disorder
OT  - zuranolone
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/31 06:42
MHDA- 2024/01/31 06:43
PMCR- 2023/01/01
CRDT- 2024/01/31 04:17
PHST- 2023/11/02 00:00 [received]
PHST- 2023/12/15 00:00 [accepted]
PHST- 2024/01/31 06:43 [medline]
PHST- 2024/01/31 06:42 [pubmed]
PHST- 2024/01/31 04:17 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fnins.2023.1332329 [doi]
PST - epublish
SO  - Front Neurosci. 2024 Jan 16;17:1332329. doi: 10.3389/fnins.2023.1332329. 
      eCollection 2023.